FIG. 4.

Immunoblots of whole-cell extracts prepared from infected V49 and Vero cells. Whole-cell extracts were prepared from HSV-1(F)-, RF177-, or mock-infected V49 and Vero cells. Equal amounts of protein from each extract were separated in 15% DATD–acrylamide, transferred to nitrocellulose, and probed with affinity-purified RGST49 (A), anti-VP16 (B and E), anti-VP13/14 (C), and G49 (D) antibodies as described in Materials and Methods. Secondary antibodies were conjugated to alkaline phosphatase (A and D) or horseradish peroxidase (B, C, and E). The locations of full-length VP22 synthesized during HSV-1(F) infection and from VP22-expressing V49 cells (VP22) and the faster-migrating, truncated form of VP22 (Δ212) expressed during RF177 infection are indicated to the right of panels A and D. VP16 marks the location of VP16 protein in panels B and E, and a vertical bar labeled VP13/14 marks the glycosylated forms of VP13/14 detected by the R220/5 antibody in panel C.